Pasireotide Evidence Guide
Pasireotide (Signifor) is FDA-approved for Cushing's disease in patients who fail surgery or are not surgical candidates, with Phase 3 data demonstrating meaningful UFC normalization. Its multi-receptor somatostatin analog profile (SST1/2/3/5) differentiates it from octreotide and allows ACTH suppression that octreotide cannot achieve. A validated, targeted treatment for a rare pituitary disorder.
Our Take
Pasireotide (Signifor) is FDA-approved for Cushing's disease in patients who fail surgery or are not surgical candidates, with Phase 3 data demonstrating meaningful UFC normalization. Its multi-receptor somatostatin analog profile (SST1/2/3/5) differentiates it from octreotide and allows ACTH suppression that octreotide cannot achieve. A validated, targeted treatment for a rare pituitary disorder.
- Best for
- Cushing's disease (ACTH-secreting pituitary adenoma), multi-receptor somatostatin pharmacology, acromegaly (LAR formulation)
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 0.6-0.9mg subcutaneous twice daily (Signifor); 40mg IM monthly (Signifor LAR)
Benefits and Evidence
- Cushing's Disease Control: Level A, includes human evidence - Phase 3 trial showed urinary free cortisol normalization in approximately 26% of patients at 6 months, with many more showing significant cortisol reduction. First medical therapy approved for Cushing's disease.
- Acromegaly Control: Level A, includes human evidence - PAOLA trial demonstrated superior GH and IGF-1 control with pasireotide LAR compared to continued octreotide LAR or lanreotide in patients inadequately controlled on first-generation somatostatin analogs.
- Hyperglycemia: Level A, includes human evidence - Hyperglycemia is the most significant adverse effect, occurring in approximately 70% of patients. Related to suppression of insulin and incretin secretion via SSTR5. Many patients require anti-diabetic therapy.
Side Effects and Warnings
- Hyperglycemia (most significant)
- Diarrhea
- Nausea
- Cholelithiasis
- Headache
- Abdominal pain
- Fatigue
- Hyperglycemia/diabetes - monitor blood glucose before and during treatment; may require anti-diabetic medication
Research Dosage References
- <strong>Subcutaneous injection</strong> - 0.3-0.9 mg - Twice daily - For Cushing's disease. Start at 0.6 mg twice daily, titrate based on urinary free cortisol response. Available as immediate-release formulation.
- <strong>Intramuscular injection</strong> - 40-60 mg - Every 28 days - Signifor LAR for acromegaly. Start at 40 mg monthly. May increase to 60 mg if inadequate response after 3 months.
Mechanism of Action
Pasireotide exerts therapeutic effects through broad somatostatin receptor activation: 1. SSTR5-predominant binding: High affinity for SSTR5, which is the predominant somatostatin receptor subtype on corticotroph adenomas, directly inhibiting ACTH secretion. 2. Multi-receptor somatostatin mimicry: Activates SSTR1, 2, 3, and 5, providing broader suppression of hormonal hypersecretion than octreotide or lanreotide. 3. ACTH suppression: Reduces adrenocorticotropic hormone (ACTH) secretion from pituitary corticotroph tumors, leading to decreased cortisol production. 4. GH/IGF-1 suppression: Inhibits growth hormone secretion in acromegaly through SSTR2 and SSTR5 activation on somatotroph adenomas.
Legal Status
FDA-approved for Cushing's disease (2012, SC formulation) and acromegaly (2014, LAR formulation). Available by prescription only. Marketed as Signifor by Recordati Rare Diseases (formerly Novartis).
Primary Sources
- Pasireotide treatment significantly reduces urinary free cortisol in Cushing's disease. J Clin Endocrinol Metab, 2012.
- Pasireotide LAR versus octreotide LAR or lanreotide in acromegaly (PAOLA). J Clin Endocrinol Metab, 2014.
- Management of pasireotide-associated hyperglycemia in Cushing's disease and acromegaly. Pituitary, 2016.